All News

Marc Humbert, MD, PhD, shared data that were presented at the ACC 2025 Scientific Sessions.

Jawad Butt, MD, offers insight into his analysis of the FINEARTS-HF trial.

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

Patients in the treatment group had a 21% lower risk of cardiovascular death or first heart failure hospitalization overall, but the between-group difference did not meet the threshold for statistical significance for this primary end point.

The trial is the first to test the cardiovascular benefits of an oral glucagon-like peptide-1 (GLP-1) agonist.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

The DapaTAVI study is the first trial of a sodium-glucose cotransporter-2 (SGLT2) inhibitor for valvular disease.

The availability of this option could make physicians more comfortable when prescribing ticagrelor, which could help solve the challenge of undertreatment with antiplatelet therapy.

Rivaroxaban offers more predictable dosing, eliminates frequent blood tests, and is less likely to interact with foods.

The STRIDE trial was first of its kind to evaluate the use of a GLP-1 agonist in PAD management.

PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, and perioperative strategies improving survival and outcomes.

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Vitamin E intake, specifically α-tocopherol, may reduce the development of peanut allergies and anaphylaxis in newborns.

Approval of durvalumab is in combination with gemcitabine and cisplatin as neoadjuvant treatment for adults with muscle invasive bladder cancer.

Colorectal cancer cases are on the rise—here is everything you need to know as an oncology pharmacist.

Approval of fitusiran, a small interfering RNA drug, was found effective in patients with hemophilia regardless of inhibitor status.

The expanded discount program offers semaglutide for $499 per month for all eligible cash-paying customers.

Kaite Krell, MPH, discusses the critical role of independent pharmacies and how proposed legislation could address challenges with PBMs.

In certain patients with chronic kidney disease (CKD), peritoneal dialysis maintained hemodynamic stability, optimal nutritional status, reduced hospitalization, and lowered diuretics reliance.

Results support a 2020 meta-analysis showing that older adults with chronic pain are nearly twice as likely to develop frailty compared to those without chronic pain.

These results align with those from shorter-term analyses of low-density lipoprotein cholesterol (LDL-C) reductions with evolocumab and cognitive impairment risk.

Greg Clyde, PharmD, shares his love of pharmacy with patients in oklahoma.

Pharmacy Times will be on-site in Chicago, Illinois from March 29 through 31.

The biosimilar is approved for all indications of the reference products, Prolia and Xgeva.

How PBMs Are Reshaping Access, Affordability, and Outcomes in Modern Health Care

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

Low-density lipoprotein cholesterol value below 88 mg/dL was associated with heightened mortality, highlighting the need for more liberal cholesterol targets in this population.

Expert emphasized the importance of mentoring pharmacy students, supporting diverse career paths, and advocating for the profession.